Transgene SA (TRGNF)
USD 1.59
(0.0%)
USD 1.59
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -22.32 Million EUR | 31.94% |
| 2022 | -32.8 Million EUR | -67.92% |
| 2021 | -19.53 Million EUR | -13.38% |
| 2020 | -17.23 Million EUR | 8.37% |
| 2019 | -18.8 Million EUR | -334.2% |
| 2018 | 8.02 Million EUR | 124.88% |
| 2017 | -32.27 Million EUR | -28.04% |
| 2016 | -25.2 Million EUR | 45.64% |
| 2015 | -46.37 Million EUR | 4.49% |
| 2014 | -48.55 Million EUR | -13.3% |
| 2013 | -42.85 Million EUR | 0.8% |
| 2012 | -43.2 Million EUR | 0.97% |
| 2011 | -43.62 Million EUR | -27.49% |
| 2010 | -34.21 Million EUR | -25.13% |
| 2009 | -27.34 Million EUR | -51.93% |
| 2008 | -18 Million EUR | -226.03% |
| 2007 | -5.52 Million EUR | 74.94% |
| 2006 | -22.03 Million EUR | 0.0% |
| 2004 | -20.48 Million EUR | 1.87% |
| 2003 | -20.87 Million EUR | -13.41% |
| 2002 | -18.4 Million EUR | 16.13% |
| 2001 | -21.94 Million EUR | 2.37% |
| 2000 | -22.47 Million EUR | -23.35% |
| 1999 | -18.22 Million EUR | 47.93% |
| 1998 | -34.99 Million EUR | -195.12% |
| 1997 | -11.85 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -8.24 Million EUR | -156.54% |
| 2024 Q2 | -8.24 Million EUR | 0.0% |
| 2023 Q4 | -3.21 Million EUR | 0.0% |
| 2023 FY | -22.32 Million EUR | 31.94% |
| 2023 Q1 | -7.95 Million EUR | 54.63% |
| 2023 Q2 | -15.9 Million EUR | -100.0% |
| 2023 Q3 | -3.21 Million EUR | 79.79% |
| 2022 Q4 | -17.52 Million EUR | -100.0% |
| 2022 FY | -32.8 Million EUR | -67.92% |
| 2022 Q2 | -15.27 Million EUR | -100.0% |
| 2022 Q3 | -8.76 Million EUR | 42.65% |
| 2022 Q1 | -7.63 Million EUR | 1.25% |
| 2021 Q1 | -5.9 Million EUR | 60.71% |
| 2021 Q3 | -3.86 Million EUR | 67.22% |
| 2021 FY | -19.53 Million EUR | -13.38% |
| 2021 Q2 | -11.8 Million EUR | -100.0% |
| 2021 Q4 | -7.73 Million EUR | -100.0% |
| 2020 Q3 | -7.5 Million EUR | -239.14% |
| 2020 Q1 | -1.1 Million EUR | 68.02% |
| 2020 Q2 | -2.21 Million EUR | -100.0% |
| 2020 Q4 | -15.01 Million EUR | -100.0% |
| 2020 FY | -17.23 Million EUR | 8.37% |
| 2019 Q2 | -15.34 Million EUR | -100.0% |
| 2019 Q1 | -7.67 Million EUR | -166.99% |
| 2019 Q3 | -1.73 Million EUR | 88.72% |
| 2019 Q4 | -3.46 Million EUR | -100.0% |
| 2019 FY | -18.8 Million EUR | -334.2% |
| 2018 FY | 8.02 Million EUR | 124.88% |
| 2018 Q1 | -7.43 Million EUR | -6.78% |
| 2018 Q2 | -7.43 Million EUR | 0.0% |
| 2018 Q3 | 11.45 Million EUR | 253.98% |
| 2018 Q4 | 11.45 Million EUR | 0.0% |
| 2017 FY | -32.27 Million EUR | -28.04% |
| 2017 Q4 | -6.96 Million EUR | 0.0% |
| 2017 Q2 | -9.17 Million EUR | 0.0% |
| 2017 Q1 | -9.17 Million EUR | -46.25% |
| 2017 Q3 | -6.96 Million EUR | 24.08% |
| 2016 Q2 | -5.81 Million EUR | 0.0% |
| 2016 FY | -25.2 Million EUR | 45.64% |
| 2016 Q4 | -6.27 Million EUR | 0.0% |
| 2016 Q3 | -6.27 Million EUR | -7.78% |
| 2016 Q1 | -5.81 Million EUR | 28.38% |
| 2015 FY | -46.37 Million EUR | 4.49% |
| 2015 Q4 | -8.12 Million EUR | 0.0% |
| 2015 Q2 | -10.82 Million EUR | 0.0% |
| 2015 Q3 | -8.12 Million EUR | 24.97% |
| 2015 Q1 | -10.82 Million EUR | -8.39% |
| 2014 Q4 | -9.99 Million EUR | 0.0% |
| 2014 Q3 | -9.99 Million EUR | 5.44% |
| 2014 Q1 | -10.56 Million EUR | -7.32% |
| 2014 FY | -48.55 Million EUR | -13.3% |
| 2014 Q2 | -10.56 Million EUR | 0.0% |
| 2013 Q2 | -11.58 Million EUR | 0.0% |
| 2013 Q4 | -9.84 Million EUR | 0.0% |
| 2013 Q3 | -9.84 Million EUR | 15.0% |
| 2013 FY | -42.85 Million EUR | 0.8% |
| 2013 Q1 | -11.58 Million EUR | 0.0% |
| 2012 FY | -43.2 Million EUR | 0.97% |
| 2011 FY | -43.62 Million EUR | -27.49% |
| 2010 FY | -34.21 Million EUR | -25.13% |
| 2009 FY | -27.34 Million EUR | -51.93% |
| 2008 FY | -18 Million EUR | -226.03% |
| 2007 FY | -5.52 Million EUR | 74.94% |
| 2006 FY | -22.03 Million EUR | 0.0% |
| 2005 Q1 | -4.38 Million EUR | -6.9% |
| 2005 Q2 | -4.7 Million EUR | -7.35% |
| 2004 Q3 | -5.94 Million EUR | -15.78% |
| 2004 Q2 | -5.13 Million EUR | 5.37% |
| 2004 Q1 | -5.42 Million EUR | 17.77% |
| 2004 Q4 | -4.09 Million EUR | 31.05% |
| 2004 FY | -20.48 Million EUR | 1.87% |
| 2003 Q2 | -5.11 Million EUR | -6.98% |
| 2003 FY | -20.87 Million EUR | -13.41% |
| 2003 Q3 | -4.37 Million EUR | 14.59% |
| 2003 Q1 | -4.78 Million EUR | -3.52% |
| 2003 Q4 | -6.59 Million EUR | -50.86% |
| 2002 Q2 | -4.76 Million EUR | 0.78% |
| 2002 FY | -18.4 Million EUR | 16.13% |
| 2002 Q1 | -4.8 Million EUR | 25.78% |
| 2002 Q3 | -4.2 Million EUR | 11.67% |
| 2002 Q4 | -4.62 Million EUR | -9.85% |
| 2001 Q2 | -5.53 Million EUR | -0.49% |
| 2001 FY | -21.94 Million EUR | 2.37% |
| 2001 Q4 | -6.46 Million EUR | -46.28% |
| 2001 Q3 | -4.42 Million EUR | 20.06% |
| 2001 Q1 | -5.5 Million EUR | -22.62% |
| 2000 Q1 | -6.52 Million EUR | -19.69% |
| 2000 FY | -22.47 Million EUR | -23.35% |
| 2000 Q4 | -4.48 Million EUR | 40.86% |
| 2000 Q3 | -7.59 Million EUR | -97.62% |
| 2000 Q2 | -3.84 Million EUR | 41.14% |
| 1999 Q1 | -3.7 Million EUR | 21.97% |
| 1999 FY | -18.22 Million EUR | 47.93% |
| 1999 Q2 | -4.55 Million EUR | -23.01% |
| 1999 Q4 | -5.45 Million EUR | -18.54% |
| 1999 Q3 | -4.6 Million EUR | -0.95% |
| 1998 Q4 | -4.74 Million EUR | 11.8% |
| 1998 Q1 | -21.74 Million EUR | 0.0% |
| 1998 Q2 | -5.62 Million EUR | 74.11% |
| 1998 Q3 | -5.38 Million EUR | 4.37% |
| 1998 FY | -34.99 Million EUR | -195.12% |
| 1997 FY | -11.85 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 70.215% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -239.532% |
| SQZ Biotechnologies Company | -79.46 Million USD | 71.902% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 142.145% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 134.281% |
| Mesoblast Limited | -87.95 Million USD | 74.615% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -1126.457% |
| Genus plc | 7.9 Million USD | 382.633% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -104.999% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -501.795% |
| Marizyme, Inc. | -65.34 Million USD | 65.832% |
| ContraFect Corporation | -65.15 Million USD | 65.73% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -152.465% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -356.973% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -1192.537% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -671.956% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -177.033% |
| MultiCell Technologies, Inc. | -380.07 USD | -5874607.291% |
| Accustem Sciences Inc. | -3.74 Million USD | -495.982% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 56.806% |
| EV Biologics, Inc. | -1.26 Million USD | -1662.087% |
| Q BioMed Inc. | -2.05 Million USD | -988.06% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -498.125% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -3430.638% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -837.808% |
| Biomind Labs Inc. | -1.21 Million USD | -1738.726% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -111.68% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -182.522% |
| Skye Bioscience, Inc. | -37.64 Million USD | 40.688% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -929.028% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -148991.88% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -219.755% |
| IMV Inc. | -36.48 Million USD | 38.803% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -40.68% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -283.824% |
| GB Sciences, Inc. | -1.36 Million USD | -1539.743% |
| Alpha Cognition Inc. | -13.77 Million USD | -62.119% |
| HST Global, Inc. | -146.21 Thousand USD | -15171.185% |
| CSL Limited | 2.64 Billion USD | 100.845% |
| Halberd Corporation | -79.67 Thousand USD | -27923.495% |
| Enzolytics Inc. | -2.17 Million USD | -925.711% |
| Resverlogix Corp. | -3.61 Million USD | -518.504% |
| Affymax, Inc. | -14.42 Million USD | -54.798% |
| SYBLEU INC | -180.3 Thousand USD | -12283.53% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -604.034% |
| argenx SE | -295.05 Million USD | 92.433% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 64.332% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 22883.673% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -461.994% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -637.839% |
| AVAX Technologies, Inc. | -6.41 Million USD | -248.133% |
| Zenith Capital Corp. | -10.59 Million USD | -110.721% |
| Genscript Biotech Corporation | -95.47 Million USD | 76.614% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -95967.464% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -438.551% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -36842.049% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 62.616% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -619.848% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -2014.28% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -1045.467% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -484.656% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1013.552% |
| BioStem Technologies, Inc. | -8.48 Million USD | -163.209% |
| ONE Bio Corp. | 8.67 Million USD | 357.335% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -4958.806% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1571.97% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -1172.417% |
| Agentix Corp. | -1.37 Million USD | -1524.787% |
| LadRx Corporation | 400.44 Thousand USD | 5675.825% |
| Cell Source, Inc. | -5.32 Million USD | -319.604% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -5274.038% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2281.517% |
| Regen BioPharma, Inc. | 1.02 Million USD | 2281.517% |
| NovAccess Global Inc. | -4.76 Million USD | -368.172% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 422.445% |
| Itoco Inc. | -1.86 Million USD | -1094.653% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -402.596% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -1237.807% |
| Kadimastem Ltd | -3.3 Million USD | -575.093% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -8066.729% |
| CytoDyn Inc. | -49.84 Million USD | 55.202% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -28151.49% |
| Mobile Lads Corp. | -2.26 Million USD | -886.528% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -9687.531% |
| Qrons Inc. | -789.34 Thousand USD | -2728.667% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -2271.462% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -969.512% |
| Rebus Holdings, Inc. | -1.02 Million USD | -2089.02% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -1284.479% |
| International Stem Cell Corporation | -131 Thousand USD | -16944.275% |
| Bioxytran, Inc. | -4.28 Million USD | -421.682% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -41040.92% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -782.443% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 53.553% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -956.197% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -2759.313% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -604.798% |
| Neutra Corp. | -233.46 Thousand USD | -9463.746% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -10.039% |
| PureTech Health plc | -65.69 Million USD | 66.014% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -4.991% |
| IXICO plc | -1.17 Million USD | -1795.416% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -124.922% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 60.916% |
| CSL Limited | 2.64 Billion USD | 100.845% |
| Cellectis S.A. | -103.17 Million USD | 78.359% |